GBI Research, a leading business intelligence provider, has released its latest research, "Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen", which provides insights into the global contraceptives market and market forecasts until 2018. The report provides an in-depth analysis of the most commonly used contraceptives, such as oral, topical, and injectable contraceptives, and devices such as intrauterine devices, condoms, and vaginal rings. The report also examines the usage patterns and annual cost of usage for these segments. It also includes insights into the contraceptives R&D product pipeline and explores the competitive landscape, including major companies in the contraceptives market. Finally, the report also includes analysis of the mergers and acquisitions (M&A) and licensing agreements that have taken place in the global contraceptives market.
The contraceptives market is growing, and more than 90 million people from seven major markets used them in 2011, with more than 24 million people having used them in the US alone. The user population is expected to grow gradually during the forecast period and reach more than 94 million in 2018.
According to GBI Research's analysis, in 2011, the contraceptives market was worth $10.2 billion, indicating a Compounded Annual Growth Rate (CAGR) of 2.7% between 2004 and 2011. By 2018, the market is expected to reach $11.8 billion, growing at a CAGR of 2.1%. The launch of the FC patch, AG200-15, Savvy Gel, LNG 20, Pill-Plus and some key products in the late stage pipeline combined with increasing awareness are expected to drive the market.
The annual cost of usage for contraceptives was $113 in 2011, which grew from $104 in 2004 at a CAGR of 1.2%. This is expected to grow to $125 in 2018, at a CAGR of 1.4% between 2011 and 2018. The growth rate can be attributed to factors such as the expected patent expiry of Mirena and Yaz. In the forecast period, CSD500, a condom manufactured by Futura Medical and licensed to Reckitt and Benckiser, is expected to strengthen the condom market.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.
- Data and analysis on the contraceptives market in leading geographies: the US, the UK, Germany, France, Italy, Spain and Japan; along with their reach in emerging markets.
- Annualized market data for oral contraceptives, topical contraceptives, injectable contraceptives, condoms, intrauterine devices and vaginal rings in the contraceptives market from 2004-2011, with forecasts to 2018.
- Market data on the therapeutic landscape, which covers oral, topical and injectable contraceptives, and includes market revenues, treatment usage patterns and the annual cost of usage.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the contraceptives market, which includes companies such as Bayer, Merck, Church & Dwight, Warner Chilcott Company, and Pfizer.
- Key M&A activities and licensing agreements that took place from 2008-2012 in the contraceptives market.
Reasons to buy
- Align your product portfolio to markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Devise a more specifically-tailored country strategy through understanding of the key drivers and barriers in the contraceptives market of all the major countries.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.